AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|

18.5 C

New York

Wednesday, November 4, 2026

Loyalty Juggernaut and On Point Loyalty Launch fidivio, the Loyalty Industry’s First Integrated Financial Planning, Analysis and IFRS-Compliant Accounting Platform

CStone and Kimia Therapeutics Enter Clinical Development Collaboration to Advance a Novel Drug Candidate Targeting Repair Pathways Critical for Solid Tumor Survival

Empowering Malaysia’s Digital Future: AWS and Elitery Celebrate Grand Finale of AWS CendekiAwan

Tag: 7736

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as...

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

HEINEKEN opens global R&D Centre in the Netherlands to lead brewing innovation and next-generation product development

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTags7736